ReviewADMET & DMPK2026
Comprehensive review of biosynthesis, plant function, metabolism and new therapeutic bioactivities of flavonoids.
Review in ADMET & DMPK, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Flavonoids are polyphenolic secondary metabolites synthesized via the phenylpropanoid pathway, serving as a vital biological "immune system" for plants by providing UV-B protection, antimicrobial defence, and pollinator attraction. Experimental approach: This review examines how these plant-based survival tools translate into potent therapeutic agents for human health through a literature review using Google Scholar, Scopus and ScienceDirect, with keywords alone or in combination with other terms. Key results: Current research demonstrates that flavonoids possess diverse bioactivities, including antioxidant, anti-inflammatory neuroprotective properties, with significant efficacy in mitigating cardiovascular disease, diabetes and cancer. Despite these benefits, the clinical application of flavonoids is currently hindered by limited bioavailability, which prevents consistent therapeutic concentrations in the human body, and a lack of standardized regulatory dosing. Conclusion: This paper identifies three critical pillars for future innovation in the development of structural analogs to (a) improve intestinal absorption, (b) explore drug synergy for enhancing conventional medical treatments and (c) evaluate the microbiome interactions to facilitate personalized nutrition. By integrating plant biochemistry with clinical pharmacology, flavonoids can be transitioned from general dietary components into precise, evidence-based therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.